Semperit (SEM) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
9 Jul, 2026Executive summary
Q3 2025 saw a significant turnaround with EBITDA up 92% versus Q1, 9% versus Q2, and 28.7% year-over-year, with earnings after tax returning to positive territory at EUR 2.8 million compared to a loss in Q3 2024.
Order intake and backlog improved over 2024, supporting confidence for the remainder of the year.
Cost-saving initiatives defined to reduce annual cost base by EUR 10 million, with EUR 4.1 million achieved by September.
Maintained a solid financial position with a 47% equity ratio and 1.5x leverage; repaid EUR 31 million Schuldschein loan in Q3.
Financial highlights
Revenue for the first nine months of 2025 was EUR 483.4 million, down 4.6% year-over-year; EBITDA was EUR 52 million, down 18.6% year-over-year, with a margin of 10.8%.
Q3 2025 revenue was EUR 162.9 million (+1.1% YoY); EBITDA EUR 21.3 million (+28.7% YoY); earnings after tax EUR 2.8 million (vs. -2.5 million prior year).
Free cash flow remained stable at EUR 22.3 million; CAPEX reduced to EUR 25.8 million for Q1-3 2025.
Net financial debt/EBITDA ratio stands at 1.5; equity ratio stable at 47%.
Dividend of EUR 0.50 per share (EUR 10.3 million) paid in April 2025.
Outlook and guidance
Full-year 2025 operating EBITDA expected at approximately EUR 78 million, before EUR 5 million in digitalization project costs.
CapEx for 2025 projected at EUR 40 million, with flexibility to adjust based on market conditions.
Seasonality expected in 2026, with a slower start and stronger second half.
Midterm growth drivers include German infrastructure, EU defense budgets, and Ukraine reconstruction.
Latest events from Semperit
- EBITDA up 21%, earnings positive, and free cash flow nearly doubled despite weak demand.SEM
Q4 20248 Jul 2026 - Q1 2026 saw strong revenue and EBITDA growth, but geopolitical and raw material risks remain.SEM
Q1 202619 May 2026 - Margin recovery, innovation, and sustainability drive a strong 2026 growth outlook.SEM
Austrian Select Conference23 Apr 2026 - Operating EBITDA beat guidance and margin rebounded; 2026 targets growth and higher profitability.SEM
Q4 202518 Mar 2026 - EBITDA up 7.9% to €47.3m, medical business divested, and cost savings exceeded targets.SEM
Q2 20241 Feb 2026 - EBITDA up 11.9% to EUR 63.9m, profit positive, and 2024 guidance reaffirmed.SEM
Q3 202416 Jan 2026 - Q1 2025 saw steep profit declines, improved cash flow, and cautious optimism for H2 recovery.SEM
Q1 202526 Nov 2025 - Q2 recovery lifted order intake and margins; full-year EBITDA guidance and CapEx confirmed.SEM
Q2 202523 Nov 2025